1. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Issue 8 (August 2022) Authors: Evans, R A; Leavy, O C; Richardson, M; Elneima, O; McAuley, H J C; Shikotra, A; Singapuri, A; Sereno, M; Saunders, R M; Harris, V C; Houchen-Wolloff, L; Aul, R; Beirne, P; Bolton, C E; Brown, J S; Choudhury, G; Diar-Bakerly, N; Easom, N; Echevarria, C; Fuld, J Journal: Lancet Issue: Volume 10:Issue 8(2022) Page Start: 761 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Idiopathic pulmonary fibrosis in a Christmas Island nuclear test veteran. (23rd November 2010) Authors: Parfrey, H; Babar, J; Fiddler, CA; Chilvers, ER Journal: BMJ case reports Issue: Volume 2010 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. M10 Persistence on antifibrotic medication in idiopathic pulmonary fibrosis (IPF) is not dependent on distance travelled to tertiary centre. (12th November 2019) Authors: Babu, A; McLellan, T; Verghese, P; Harris, E; Harding, K; Simler, N; Fiddler, C; Parfrey, H; Woodhead, F; Thillai, M Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. M15 Antifibrotic medications for idiopathic pulmonary fibrosis (IPF): a real world single centre experience of 447 patients over a 6 year period. (12th November 2019) Authors: Harris, E; Harding, K; McLellan, T; Babu, A; Verghese, P; Parfrey, H; Simler, N; Fiddler, C; Thillai, M Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. M272 Estimated Cost And Payment By Results (pbr) Tariff Reimbursement For Idiopathic Pulmonary Fibrosis Services Across 14 Specialist Providers In England. (10th November 2014) Authors: Hill, C; Nasr, R; Fisher, MI; Maher, T; Spiteri, M; Allen, M; Birring, S; Parfrey, H; Hoyles, RK; Gibbons, M; Burge, G; Scullion, J; Adams, E; Wickremasinghe, M Journal: Thorax Issue: Volume 69(2014)Supplement 2 Page Start: A222 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P155 Use of mycophenolate mofetil and azathioprine in patients with chronic hypersensitivity pneumonitis. (15th November 2017) Authors: Fiddler, CA; Simler, N; Thillai, M; Parfrey, H Journal: Thorax Issue: Volume 72(2017)Supplement 3 Page Start: A167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P196 Healthcare utilisation by patients with Idiopathic Pulmonary Fibrosis; observations from the UK pirfenidone Named Patient Programme. (14th November 2013) Authors: Parfrey, H; Leonard, C; Gibbons, MA; Armstrong, E; Harris, E; Frank, R; Sharp, C; Percival, F Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A164 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P22 Endoplasmic Reticulum Stress Markers Correlate With Fibrosis In Idiopathic Pulmonary Fibrosis And Non-specific Interstitial Pneumonia. (10th November 2014) Authors: Parfrey, H; Beardsley, B; Knight, J; Marciniak, SJ; Rassl, D Journal: Thorax Issue: Volume 69(2014)Supplement 2 Page Start: A87 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P280 Extended Clinical Experience With Pirfenidone During A Named Patient Programme For Idiopathic Pulmonary Fibrosis (ipf): Interim Results. (10th November 2014) Authors: Parfrey, H; Chaudhuri, N; Gibbons, MA; Anning, L; Balkin, M; Cooper, S; Dew, R; Maher, TM Journal: Thorax Issue: Volume 69(2014)Supplement 2 Page Start: A196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P9 Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis – initial clinical experience in a UK cohort. (12th November 2015) Authors: Fletcher, SV; Jones, MG; Renzoni, E; Parfrey, H; Hoyles, R; Spinks, K; Kokosi, M; Kwok, A; Warburton, C; Titmuss, V; Maher, T; Chua, F; Wells, A; Richeldi, L; Spencer, LG Journal: Thorax Issue: Volume 70(2015)Supplement 3 Page Start: A78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗